Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026

ROCKET PHARMACEUTICALS, INC.

2025-FY EPS reported -$2.01

Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.
Cash, cash equivalents & investments $188.9M; runway into Q2 2027; restructuring charges $3.2M.
Pivotal Phase 2 trial of RP-A501 (Danon disease) to resume 1H 2026 after FDA lifted clinical hold.
KRESLADI BLA resubmission accepted; PDUFA target action date March 28, 2026; eligible for PRV.
First patient dosing in Phase 1 RP-A701 (BAG3-DCM) expected mid-2026; Phase 1 trial startup ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.